💞 #Gate Square Qixi Celebration# 💞
Couples showcase love / Singles celebrate self-love — gifts for everyone this Qixi!
📅 Event Period
August 26 — August 31, 2025
✨ How to Participate
Romantic Teams 💑
Form a “Heartbeat Squad” with one friend and submit the registration form 👉 https://www.gate.com/questionnaire/7012
Post original content on Gate Square (images, videos, hand-drawn art, digital creations, or copywriting) featuring Qixi romance + Gate elements. Include the hashtag #GateSquareQixiCelebration#
The top 5 squads with the highest total posts will win a Valentine's Day Gift Box + $1
Hanyu Pharmaceutical: The enrollment of all subjects in the Phase III clinical trial for the weight loss indication of Semaglutide Injection has been completed.
On June 12, Hanyu Pharmaceutical said on the interactive platform that the company's semaglutide injection was declared for marketing in accordance with Class 2.2, of which the bariatric indication had completed the enrollment of all subjects in the phase III clinical trial in January this year, and was currently in the follow-up stage, and the project had entered the dose maintenance period. After the completion of the Phase III clinical trial in the future, the Company will submit a marketing application after collating and improving the clinical trial data in accordance with relevant regulatory requirements.